Eli Lilly and Co., of Indianapolis, said it accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, and will extend the phase III trial of evacetrapib, a selective inhibitor of cholesteryl ester transfer protein, by approximately six months.